COVID-19 infection comes with hemostasis disorders related to the inflammation and endothelial damage and leads to an increased risk of thrombosis. A recent study suggests that SARS-CoV-2 may infect vascular endothelial cells at an early stage in the disease. Various complications have been observed to date – thrombotic complications in the short-term and probably in the medium and long term, occurrence of vascular complications … Two study populations are considered:
- study of the acute phase of mechanisms involved in the occurrence of thrombotic events. The objective is to characterize endothelial and hemostasis dysfunction in patients affected with COVID-19.
- the medium-term study of the consequences of this hemostasis deregulation in patients with a TAVI valve prosthesis, who are both at high risk for SARS-Cov-2 infection and at risk for valvular complications, particularly thrombotic complications.
To assess the impact of COVID-19 on acute phase thrombotic complications in patients hospitalized for low respiratory infection and on the risk of complications of TAVI aortic valve bioprosthetics in the Lille WITAVI cohort. To understand mechanisms leading to mild to severe disease, describing vascular endothelial dysfunction and hemostasis dysfunctions and characterize the evolution of this endotheliopathy during the disease.